That 3 years of hyper growth that you mention converts to an increase in total revenue of 3.5x over that 3 years. Not too shabby at all. IMO this certainly proves the market is rapidly replacing old, inferior products with novosorb because of the much better outcomes for patients at less cost.
In my experience no stock of this type has the same steady % growth in each quarter and in each market. The normal is to have some fluctuations on the path up. I would not read too much into the US sales only going up from $32.2M in the first half to $36.5M in the second. I have little doubt that total sales will double in the next 2 years based on everything I see happening.
Ann: FY24 Trading Result (unaudited), page-67
-
- There are more pages in this discussion • 123 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.49 |
Change
-0.120(4.60%) |
Mkt cap ! $1.718B | |||
| Open | High | Low | Value | Volume |
| $2.69 | $2.74 | $2.49 | $5.988M | 2.290M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 38045 | $2.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.51 | 27863 | 3 |
View Market Depth
| Last trade - 16.10pm 26/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |